00:41 , Feb 9, 2018 |  BC Innovations  |  Product R&D

R is for readout

While AstraZeneca plc gets credit for transparency in publishing its metrics on R&D productivity, the data cover well-established targets addressed by conventional modalities. The more telling test for its “5R framework” will be whether it...
22:34 , Sep 5, 2017 |  BC Extra  |  Clinical News

Insmed jumps on Phase III success in rare lung infection

Insmed Inc. (NASDAQ:INSM) soared $14.70 (120%) to $26.99 on Tuesday and ended the day with about $1.7 billion in market cap after reporting that ALIS (amikacin liposome inhalation suspension, Arikayce) met the primary endpoint of...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

AstraZeneca, Insmed deal

AstraZeneca granted Insmed exclusive, worldwide rights to INS1007 (formerly AZD7986), a small molecule targeting dipeptidyl peptidase-1 ( DPP-1; CTSC). AZ will receive $30 million up front and is eligible for up...
07:00 , Oct 5, 2016 |  BC Extra  |  Company News

Insmed in-licenses DPP-1 inhibitor from AstraZeneca

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted pulmonary disease company Insmed Inc. (NASDAQ:INSM) exclusive, worldwide rights to AZD7986, a small molecule inhibitor of dipeptidyl peptidase-1 ( DPP-1; CTSC). The candidate, which Insmed renamed INS1007, has completed Phase...
07:00 , Sep 28, 2009 |  BC Week In Review  |  Company News

SARomics Biostructures, Unizyme deal

SARomics will use its structure-based drug design technologies to identify drug candidates targeting dipeptidyl peptidase-1 ( DPP-1) to treat inflammatory diseases for Unizyme. Unizyme will provide the small molecules for screening and will have...